Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MannKind Corporation stock logo
MNKD
MannKind
$3.93
-0.9%
$4.05
$3.51
$7.63
$1.19B0.962.43 million shs981,963 shs
Novavax, Inc. stock logo
NVAX
Novavax
$6.99
+0.4%
$6.85
$5.01
$17.81
$1.13B2.696.18 million shs3.33 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.39
+1.8%
$1.32
$1.21
$2.04
$1.10B1.343.83 million shs2.10 million shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$4.87
+1.1%
$4.52
$3.81
$6.36
$286.13M0.68577,133 shs153,596 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MannKind Corporation stock logo
MNKD
MannKind
+2.86%+3.66%+3.94%-12.78%-34.00%
Novavax, Inc. stock logo
NVAX
Novavax
+1.16%-1.14%-1.00%+16.00%-57.66%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+2.26%-1.45%+2.26%-4.23%-5.56%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
+1.05%-4.18%+5.02%+11.09%-22.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
MannKind Corporation stock logo
MNKD
MannKind
2.723 of 5 stars
3.60.00.00.02.71.71.9
Novavax, Inc. stock logo
NVAX
Novavax
4.3266 of 5 stars
3.11.00.04.71.70.83.1
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.1811 of 5 stars
3.50.00.04.43.53.30.6
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
4.7006 of 5 stars
3.84.00.04.21.53.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MannKind Corporation stock logo
MNKD
MannKind
3.25
Buy$10.14158.42% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.29
Hold$17.00143.38% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
3.00
Buy$2.7598.56% Upside
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
3.50
Strong Buy$16.50239.16% Upside

Current Analyst Ratings Breakdown

Latest VNDA, NVAX, MNKD, and OPK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
MannKind Corporation stock logo
MNKD
MannKind
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$9.00
7/8/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/17/2025
Novavax, Inc. stock logo
NVAX
Novavax
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell$6.00
5/19/2025
Novavax, Inc. stock logo
NVAX
Novavax
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/14/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$13.00
5/13/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/9/2025
Novavax, Inc. stock logo
NVAX
Novavax
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.00
5/7/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
4/25/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MannKind Corporation stock logo
MNKD
MannKind
$285.50M4.18$0.14 per share27.74($0.29) per share-13.53
Novavax, Inc. stock logo
NVAX
Novavax
$682.16M1.66N/AN/A($3.89) per share-1.80
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.10M1.54$0.07 per share19.33$2.00 per share0.69
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$201.35M1.42N/AN/A$9.24 per share0.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MannKind Corporation stock logo
MNKD
MannKind
$27.59M$0.1039.2517.07N/A10.12%-32.41%10.85%8/6/2025 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$187.50M$2.652.6487.310.0638.14%-115.51%29.99%8/14/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$53.22M-$0.07N/AN/AN/A-5.66%-2.85%-1.82%8/6/2025 (Estimated)
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$18.90M-$0.75N/AN/AN/A-21.98%-8.30%-6.85%7/30/2025 (Estimated)

Latest VNDA, NVAX, MNKD, and OPK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Novavax, Inc. stock logo
NVAX
Novavax
-$0.12N/AN/AN/AN/AN/A
8/6/2025Q2 2025
MannKind Corporation stock logo
MNKD
MannKind
$0.04N/AN/AN/A$77.82 millionN/A
8/6/2025Q2 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.11N/AN/AN/A$165.74 millionN/A
7/30/2025Q2 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.34N/AN/AN/A$54.77 millionN/A
5/8/2025Q1 2025
MannKind Corporation stock logo
MNKD
MannKind
$0.03$0.04+$0.01$0.04$75.86 million$78.35 million
5/8/2025Q1 2025
Novavax, Inc. stock logo
NVAX
Novavax
$0.71$2.93+$2.22$2.93$204.08 million$666.66 million
5/7/2025Q1 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 million
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MannKind Corporation stock logo
MNKD
MannKind
N/A
2.36
2.11
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.06
2.03
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.25
2.49
2.28
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/A
3.93
3.91

Institutional Ownership

CompanyInstitutional Ownership
MannKind Corporation stock logo
MNKD
MannKind
49.55%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
88.14%

Insider Ownership

CompanyInsider Ownership
MannKind Corporation stock logo
MNKD
MannKind
2.70%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
10.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
MannKind Corporation stock logo
MNKD
MannKind
400303.93 million295.73 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990161.97 million160.35 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
2,997793.05 million398.99 millionOptionable
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
29058.93 million53.04 millionOptionable

Recent News About These Companies

VNDA - Vanda Pharmaceuticals Inc Chart - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

MannKind stock logo

MannKind NASDAQ:MNKD

$3.92 -0.04 (-0.88%)
As of 02:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Novavax stock logo

Novavax NASDAQ:NVAX

$6.98 +0.03 (+0.36%)
As of 02:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.38 +0.03 (+1.84%)
As of 02:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Vanda Pharmaceuticals stock logo

Vanda Pharmaceuticals NASDAQ:VNDA

$4.86 +0.06 (+1.14%)
As of 02:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.